FluoroPharma, a developer of imaging drugs that underpin important diagnostic capabilities of positron emission tomography (PET), targets a fast-growing market. This market is currently over $7 billion in size and is expected to top $15 billion in 2015.
One of the elements driving this growth is the increasing demand for personalized medicine, something that requires a clear and accurate view of key biological processes occurring deep within the body. Other market drivers include an aging population and the growing demand for cost-effective imaging technologies in the Asia-Pacific market. Cardiology and neurology remain two of the industry’s strongest growth opportunities. In the case of FluoroPharma, the current focus is on cardiovascular (CV) disease and Alzheimer’s disease, with imaging drug products that allow PET scans to display in exquisite detail processes that can lead to such diseases.
One in three adults have some form of CV disease, and PET molecular imaging offers superior image quality, but there are no widely adopted PET drug agents in cardiology. FluoroPharma has three products directly addressing the CV market:
• BFPET – For measuring cardiovascular blood flow, in combination with stress testing in patients with presumptive chronic cardiovascular disease, BFPET has the potential to become the new “standard” and replace SPECT (Single-Photon Emission Computed Tomography) in institutions with PET capability.
• CardioPET – For detecting regions of fatty acid uptake, CardioPET is for the diagnosis of acute and chronic CAD in patients that cannot undergo stress testing.
• VasoPET – For detecting inflamed plaques, which are plaques most likely to rupture and cause a heart attack or sudden death.
FluoroPharma is also developing AZPET, an amyloid deposit imaging agent for the early detection of Alzheimer’s disease.
For more information, visit www.FluoroPharma.com
Let us hear your thoughts below: